Clinical Trials Logo

Stage IIIB Breast Cancer clinical trials

View clinical trials related to Stage IIIB Breast Cancer.

Filter by:

NCT ID: NCT01776008 Terminated - Clinical trials for Stage IIIA Breast Cancer

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well Akt inhibitor MK-2206 (MK-2206) and anastrozole with or without goserelin acetate works in treating patients with stage II-III breast cancer. MK-2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole and goserelin acetate may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving MK-2206, anastrozole, and goserelin acetate together may kill more tumor cells.

NCT ID: NCT01755208 Terminated - Clinical trials for Stage IIIA Breast Cancer

Light-Scattering Spectroscopy for Detection of Breast Cancer

Start date: November 21, 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies light-scattering spectroscopy in finding disease in patients with stage II-III breast cancer. Diagnostic procedures, such as light-scattering spectroscopy, may help find and diagnose breast cancer

NCT ID: NCT01750073 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Start date: December 7, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well giving paclitaxel and cyclophosphamide with or without trastuzumab before surgery works in treating patients with previously untreated breast cancer. Drugs used in chemotherapy, such as paclitaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, may block tumor growth in different ways by targeting certain cells. Giving combination chemotherapy with or without trastuzumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT01730833 Active, not recruiting - Clinical trials for HER2-positive Breast Cancer

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

Start date: July 17, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation work in treating patients with human epidermal growth factor receptor (HER) 2-positive stage II-IV breast cancer. Monoclonal antibodies, such as pertuzumab and trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to kill tumor cells or stop them from growing. Giving pertuzumab and trastuzumab together with paclitaxel albumin-stabilized nanoparticle formulation may be a better way to block tumor growth.

NCT ID: NCT01729832 Withdrawn - Clinical trials for Stage IV Breast Cancer

Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer

Start date: January 10, 2011
Phase: N/A
Study type: Interventional

Many hospitals, including the Ohio State University Medical Center, will take pictures of the blood vessels in a patient's abdomen before they decide to perform a breast reconstruction using the patient's own tissue. These pictures are called computed tomography (CT) angiograms and are like a map of each patient's anatomy. However, no study has been reported that determined how accurate these pictures are at showing the surgeon where all of the blood vessels were located. This study will try to determine if these pictures are missing any blood vessels that are found during surgery and if the pictures show the correct location of the vessels

NCT ID: NCT01723943 Completed - Depression Clinical Trials

Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients

Start date: March 2009
Phase: N/A
Study type: Interventional

This randomized clinical trial studies educational counseling in improving communication and quality of life in spouses and breast cancer patients. An outpatient education and behavior skills training program may help spouses and patients with breast cancer communicate better and improve quality of life. It is not yet known whether educational counseling is more effective than an educational booklet in improving communication and quality of life.

NCT ID: NCT01712815 Terminated - Clinical trials for HER2-positive Breast Cancer

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

Start date: November 22, 2013
Phase: N/A
Study type: Interventional

This phase I trial studies the side effects of positron emission tomography (PET)/computed tomography (CT) in evaluating response to chemotherapy in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

NCT ID: NCT01697293 Terminated - Clinical trials for Stage IV Breast Cancer

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and the best dose of triciribine phosphate when given together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide and to see how well they work in treating patients with stage IIB-IV breast cancer. Triciribine phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving triciribine phosphate with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide may be a better treatment for breast cancer.

NCT ID: NCT01672684 Completed - Depression Clinical Trials

Phase I: At-Home Support for Rural Women Using Group Video Calling

Start date: October 2012
Phase: Phase 1
Study type: Interventional

This randomized phase I trial studies at-home group video calling sessions in quality of life in rural patients with breast cancer. At-home group video calling support sessions may improve the well-being and quality of life of women who have breast cancer

NCT ID: NCT01632332 Completed - Clinical trials for HER2-positive Breast Cancer

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

Start date: July 9, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor receptor 2) positive breast cancer.